Rivaroxaban

Generic Name
Rivaroxaban
Brand Names
Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
Drug Type
Small Molecule
Chemical Formula
C19H18ClN3O5S
CAS Number
366789-02-8
Unique Ingredient Identifier
9NDF7JZ4M3
Background

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...

Indication

Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...

Associated Conditions
Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
Associated Therapies
-
Clinical Trials
Related News

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Phase 2
Active, not recruiting
Conditions
Atrial Fibrillation (AF)
Stroke
Interventions
Biological: Abelacimab
Drug: Rivaroxaban
First Posted Date
2021-02-16
Last Posted Date
2024-07-23
Lead Sponsor
Anthos Therapeutics, Inc.
Target Recruit Count
1200
Registration Number
NCT04755283
Locations
🇭🇺

Anthos Investigative Site (4002), Nyíregyháza, SZ, Hungary

🇭🇺

Anthos Investigative Site (4003), Nyíregyháza, SZ, Hungary

🇨🇳

Anthos Investigative Site, Tiachung, TXG, Taiwan

Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data

First Posted Date
2021-02-03
Last Posted Date
2023-07-28
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
78605
Registration Number
NCT04736420
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19

First Posted Date
2021-02-03
Last Posted Date
2022-07-20
Lead Sponsor
Ain Shams University
Target Recruit Count
90
Registration Number
NCT04736901
Locations
🇪🇬

Teachers Hospital, Cairo, Please Select, Egypt

Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting

First Posted Date
2021-01-05
Last Posted Date
2024-05-10
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
172
Registration Number
NCT04694248
Locations
🇨🇳

The First Affliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China

NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications

First Posted Date
2020-12-10
Last Posted Date
2024-01-26
Lead Sponsor
Malmö University
Target Recruit Count
216
Registration Number
NCT04662515
Locations
🇸🇪

Skåne University Hospital, Helsingborg, Sweden

🇸🇪

Department of Oral and Maxillofacial Surgery and Oral Medicine, Faculty of Odontology, Malmö University, Malmö, Sweden

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

Phase 4
Recruiting
Conditions
Atrial Fibrillation
Interventions
Drug: Apixaban
Drug: Rivaroxaban
First Posted Date
2020-11-24
Last Posted Date
2024-10-15
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
3018
Registration Number
NCT04642430
Locations
🇨🇦

University Ottawa Heart Institute, Ottawa, Ontario, Canada

🇨🇦

CISSS de l'Outaouais, Gatineau, Quebec, Canada

🇨🇦

Ciusss Nim, Montreal, Quebec, Canada

and more 5 locations

Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)

Phase 2
Completed
Conditions
Covid19
Interventions
Drug: Rivaroxaban
Drug: Enoxaparin
First Posted Date
2020-11-23
Last Posted Date
2021-06-30
Lead Sponsor
St. David's HealthCare
Target Recruit Count
150
Registration Number
NCT04640181
Locations
🇺🇸

St. David's Medical Center, Austin, Texas, United States

Anticoagulation in Patients With Venous Thromboembolism and Cancer

First Posted Date
2020-11-06
Last Posted Date
2024-10-07
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT04618913
Locations
🇬🇧

Pfizer Investigational Site, London, United Kingdom

Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data

First Posted Date
2020-10-19
Last Posted Date
2023-07-28
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
102636
Registration Number
NCT04593056
Locations
🇺🇸

Brigham And Women's Hospital, Boston, Massachusetts, United States

Rivaroxaban vs. Warfarin in CVT Treatment

Phase 3
Completed
Conditions
Cerebral Vein Thrombosis
Interventions
Drug: Warfarin
Drug: Rivaroxaban
First Posted Date
2020-09-29
Last Posted Date
2023-02-16
Lead Sponsor
Damascus University
Target Recruit Count
71
Registration Number
NCT04569279
Locations
🇸🇾

Damascus University, Damascus, Damascus Governorate, Syrian Arab Republic

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy